Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)

Yifei Zhang, Yanyun Gu, Huahui Ren, Shujie Wang, Huanzi Zhong, Xinjie Zhao, Jing Ma, Xuejiang Gu, Yaoming Xue, Shan Huang, Jialin Yang, Li Chen, Gang Chen, Shen Qu, Jun Liang, Li Qin, Qin Huang, Yongde Peng, Qi Li, Xiaolin Wang, Ping Kong, Guixue Hou, Mengyu Gao, Zhun Shi, Xuelin Li, Yixuan Qiu, Yuanqiang Zou, Huanming Yang, Jian Wang, Guowang Xu, Shenghan Lai, Junhua Li (), Guang Ning and Weiqing Wang ()
Additional contact information
Yifei Zhang: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Yanyun Gu: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Huahui Ren: BGI-Shenzhen
Shujie Wang: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Huanzi Zhong: BGI-Shenzhen
Xinjie Zhao: Chinese Academy of Science
Jing Ma: Shanghai Jiao Tong University School of Medicine
Xuejiang Gu: The First Affiliated hospital of Wenzhou Medical University
Yaoming Xue: Southern Medical University
Shan Huang: Shanghai Jiao Tong University School of Medicine
Jialin Yang: Central Hospital of Minhang District
Li Chen: Qilu Hospital of Shandong University
Gang Chen: Fujian Provincial Hospital
Shen Qu: Shanghai Tenth People’s Hospital of Tong Ji University
Jun Liang: Xuzhou Central Hospital
Li Qin: Shanghai Jiao Tong University School of Medicine
Qin Huang: Second Military Medical University
Yongde Peng: Shanghai Jiao Tong University School of Medicine
Qi Li: Chinese Academy of Science
Xiaolin Wang: Chinese Academy of Science
Ping Kong: BGI-Shenzhen
Guixue Hou: BGI-Shenzhen
Mengyu Gao: BGI-Shenzhen
Zhun Shi: BGI-Shenzhen
Xuelin Li: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Yixuan Qiu: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Yuanqiang Zou: BGI-Shenzhen
Huanming Yang: BGI-Shenzhen
Jian Wang: BGI-Shenzhen
Guowang Xu: Chinese Academy of Science
Shenghan Lai: Johns Hopkins University School of Medicine
Junhua Li: BGI-Shenzhen
Guang Ning: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Weiqing Wang: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Nature Communications, 2020, vol. 11, issue 1, 1-12

Abstract: Abstract Human gut microbiome is a promising target for managing type 2 diabetes (T2D). Measures altering gut microbiota like oral intake of probiotics or berberine (BBR), a bacteriostatic agent, merit metabolic homoeostasis. We hence conducted a randomized, double-blind, placebo-controlled trial with newly diagnosed T2D patients from 20 centres in China. Four-hundred-nine eligible participants were enroled, randomly assigned (1:1:1:1) and completed a 12-week treatment of either BBR-alone, probiotics+BBR, probiotics-alone, or placebo, after a one-week run-in of gentamycin pretreatment. The changes in glycated haemoglobin, as the primary outcome, in the probiotics+BBR (least-squares mean [95% CI], −1.04[−1.19, −0.89]%) and BBR-alone group (−0.99[−1.16, −0.83]%) were significantly greater than that in the placebo and probiotics-alone groups (−0.59[−0.75, −0.44]%, −0.53[−0.68, −0.37]%, P

Date: 2020
References: Add references at CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
https://www.nature.com/articles/s41467-020-18414-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-18414-8

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-18414-8

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().